Trial Profile

Safety and Effectiveness of Xofigo (Radium-223 Dichloride) in Routine Clinical Practice Settings in Taiwan

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 23 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Radium 223 chloride (Primary)
Indications Adenocarcinoma; Prostate cancer
Focus Adverse reactions
Acronyms RAPIT
Sponsors Bayer

Most Recent Events

17 Jul 2024 Status changed from active, no longer recruiting to completed.
18 Feb 2023 Results (n=224; from July 2020 to January 2022) assessing the safety and effectiveness of Ra-223 in patients with metastatic castration-resistant prostate cancer and symptomatic bone metastases under routine clinical practice in Taiwan, presented at the 2023 Genitourinary Cancers Symposium.
10 Feb 2023 Planned End Date changed from 31 Mar 2024 to 30 Jun 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com